Abstract Antimicrobial therapy is a mainstay of the management for patients with acute cholangitis and/or cholecystitis. The Tokyo Guidelines 2018 (TG18) provides recommendations for the appropriate use of antimicrobials for community-acquired and healthcare-associated infections. The listed agents are for empirical therapy provided before the infecting isolates are identified. Antimicrobial agents are listed by classdefinitions and TG18 severity grade I, II, and III subcategorized by clinical settings. In the era of emerging and increasing antimicrobial resistance, monitoring and updating local antibiograms is underscored. Prudent antimicrobial usage and early de-escalation or termination of antimicrobial therapy are now important parts of decision-making. What is new in TG18 is that the duration of antimicrobial therapy for both acute cholangitis and cholecystitis is systematically reviewed. Prophylactic antimicrobial usage for elective endoscopic retrograde cholangiopancreatography is no longer recommended and the section was deleted in TG18. Free full articles and mobile app of TG18 are available at: http://www.jshbps.jp/modules/en/index.php?content_id=47. Related clinical questions and references are also included.
Introduction
The Tokyo Guidelines 2013 (TG13) antimicrobial therapy for acute cholangitis and cholecystitis, international practice guidelines for the management of patients with acute cholangitis and cholecystitis [1] have been reviewed and revised along with other parts of the therapy for the patients with acute cholangitis and cholecystitis [2] [3] [4] [5] [6] . This paper provides the Tokyo Guidelines 2018 (TG18) antimicrobial therapy for acute cholangitis and cholecystitis.
In the TG18 guidelines, empiric therapy is defined as antimicrobial therapy until the cultures and susceptibility testing results are available. Once causative microorganisms and the susceptibility testing results are available, antimicrobial therapy should be adjusted to specific antimicrobial agents targeting the organisms. This process is defined as de-escalation of antimicrobial therapy in the TG18 guidelines [7] .
Role of antimicrobial therapy
Acute cholangitis and cholecystitis are still fatal diseases if not appropriately treated in a timely fashion. In previous guidelines (TG13), we defined a severity grading system. A recent large-scale study indicated the mortality rate (30-day all-cause mortality rate) of 2.4%, 4.7%, 8.4% by TG13 severity grade I, II, and III, respectively [8] . For patients with septic shock, appropriate antimicrobial therapy should be administered within an hour [7] . For other, less acutely ill patients, therapy should be administered within 6 h of diagnosis. The primary goal of antimicrobial therapy in acute cholangitis and cholecystitis is to limit both the systemic septic response and local inflammation, to prevent surgical site infections in the superficial wound, fascia, or organ space, and to prevent intrahepatic abscess formation [9] .
While drainage of the obstructed biliary trees (termed source control) has been recognized as the mainstay of the therapy for patients with acute cholangitis [9] , the roles of antimicrobial therapy for acute cholangitis is to allow patients to have elective drainage procedures other than emergency [10] . Boey and Way retrospectively reviewed 99 consecutive patients with acute cholangitis, and reported that 53% of their patients who responded well to antimicrobial therapy were therefore provided elective instead of emergency operation [9, 10] .
For acute cholecystitis, the role of antimicrobial therapy varies depending on the severity and pathology. In early and non-severe cases (or patients with acute cholecystitis of TG18 severity grade I [11] ), it is not obvious that bacteria play a significant role in the pathology encountered. In these patients, antimicrobial therapy is at best prophylactic, preventing progression to infection. In more progressed, moderately severe or severe cases, with clinical findings of a systemic inflammatory response, antimicrobial therapy is therapeutic, and antimicrobial therapy may be required until the gallbladder is removed [12] .
Decision process A systematic literature review was performed using PubMed and Cochrane Clinical Controlled Trials (CCT) and Cochrane Database of Systematic Reviews (CDSR) from 1 January 2010 to 16 December 2016. All references were searched with the keywords "Acute cholangitis" AND "Antibiotics OR Antimicrobial therapy," and "Acute cholecystitis" AND "Antibiotics OR Antimicrobial therapy" among human studies. These references were further narrowed using "Clinical trials" and "Randomized trials." Literature cited in the TG07 [13, 14] and TG13 [1] was also reviewed and integrated for revision. In making recommendations, a consensus process utilizing the GRADE systems [15, 16] was used by the members of the Tokyo Guidelines Revision Committee. GRADE stands for Grades of Recommendation Assessment, Development, and Evaluation. In the TG18 guidelines, the strength of the recommendation was graded as 1 (strong) or 2 (weak). The quality of the evidence was graded as high (level A), moderate (level B), low (level C), and very low (level D). Newly identified literatures cited in the TG18 were mentioned in the clinical question sections.
Microbiology of acute cholangitis and cholecystitis
The bacteria commonly found in biliary tract infections are well known, and are presented in Tables 1 and 2 [8, 13, 14, [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] . A large-scale multicenter international observational study was conducted and published in 2017 on epidemiology and microbiology among patients with acute cholangitis [8] . In this study, the most frequently isolated organisms were Escherichia coli across the severity grades of TG13 [30] .
Local prevalence of extended-spectrum beta-lactamase and carbapenemase producing Gram-negative bacilli Antimicrobial therapy largely depends on local antimicrobial susceptibility data. The emergence of antimicrobial resistance among clinical isolates of Enterobacteriaceae from patients with community-acquired intra-abdominal infections has been widely reported [29, [31] [32] [33] [34] [35] [36] [37] . Especially, extended-spectrum beta-lactamases (ESBL) and carbapenemases (i.e. metallo-beta-lactamase and nonmetallo-beta-lactamase) producing bacilli reported [38] [39] [40] [41] [42] have been significantly affecting the selection of empirical therapy for patients with intra-abdominal infections, including acute cholangitis and cholecystitis [43] .
In selecting empirical antimicrobial therapy, special attention should be paid to the incidence of ESBL and carbapenemase-producing bacteria in non-urinary tract isolates. A prospective cohort study in patients with acute cholecystitis involving 116 institutions worldwide showed that among 96 isolated E. coli, 16 (16.7%) were producing ESBL [44] . However, the proportion of ESBL producing E. coli varies widely region to region: 31.2% in two German university hospitals [45] , 70.0% in Korean university medical center [46] and 66% in Indian medical college hospital [47] . There are few reports about the prevalence of carbapenem resistant bacteria specifically among patients with acute cholangitis and cholecystitis. One from Korea reported 13 out of 376 (3.5%) isolates in bile were carbapenemase producing [48] .
In TG18, the international practice guidelines for acute cholangitis and cholecystitis, agents appropriate for use are provided in Table 3 by antimicrobial class-based definitions. Table 3 has been re-evaluated with a systematic literature review and Tokyo Guidelines Revision Committee. There was no new significant evidence to modify the list of agents. Therefore, Table 3 has been endorsed from TG13, Table 3 [1] . Table 3 lists antimicrobial agents appropriate for use for the treatment of patients with both community-acquired and healthcare-associated cholangitis and cholecystitis.
Monitoring and updating local antibiograms are critical to provide effective therapy in a timely fashion in the clinical setting. We recommend that microbiology laboratories report resistance data by site of infection, and include biliary infections with other intra-abdominal infections. We also recommend empiric therapy for resistant isolates if they occur in more than 20% of patients [49] .
In particular, ampicillin/sulbactam can be used as initial therapy if the susceptibility remains over 80% in the local area. However, in many places of the world, its susceptibility has been reported to be decreasing. Ampicillin/sulbactam can be used once its susceptibility is known as definitive or targeted therapy.
Clinical questions
Clinically relevant questions are provided with brief answers and explanations below.
Questions 1 and 2, and their answers and explanations have been endorsed from TG13 Q1 and Q2 [1] .
Q1. What specimen should be sent for culture to identify the causative organisms in acute cholangitis and cholecystitis?
(Bile cultures) Bile cultures should be obtained at the beginning of any procedure performed. Gallbladder bile should be sent for culture in all cases of acute cholecystitis except those with grade I severity. (Recommendation 1, level C) Table 2 is cited from the Tokyo Guidelines 2013 (TG13) [1] . Data from Gomi et al. [8] was integrated for the Tokyo Guidelines 2018 (TG18) a Data are from references [8, [25] [26] [27] 29] b Data are from reference [29] Table 1 is cited from the Tokyo Guidelines 2013 (TG13) [1] . Data from Rhodes et al. [7] was integrated for the Tokyo Guidelines 2018 (TG18). The data are from references [8, 13, 14, [17] [18] [19] [20] [21] [22] [23] [24] 27] a A recent study by Salvador et al. [24] reported none from bile cultures, while a study by Sung et al. [29] reported 3.6% from blood cultures among community-acquired (2%) and healthcare-associated (4%) bacteremic acute biliary infections Identifying the causative organism(s) is an essential step for the management of acute biliary infections. Positive rates of bile cultures range from 28% to 93% for acute cholangitis [8, [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] and positive rates of either bile or gallbladder cultures range from 29% to 54% for acute cholecystitis [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] . In a recent study, which used the TG07 diagnostic classification, positive rates of bile cultures among patients with cholangitis were 67% (66 of 98 patients) and 33% (32 of 98) without [24] . Table 1 demonstrates common microbial isolates from bile cultures among patients with acute biliary infections [8, [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] . Common duct bile should be sent in all cases of suspected cholangitis.
On the other hand, previous studies indicated that positive rates of blood cultures among patients with acute cholangitis ranged from 21% to 71% [13] . A recent multicenter study of patients with acute cholangitis showed the proportions of positive blood cultures were 15.2%, 21%, and 25.7% by TG13 severity grade I, II, and III, respectively [7] . For acute cholecystitis, the prevalence of positive blood cultures is less than acute cholangitis, and in the last two decades it has been reported to range from 7.7% to 15.8% [25, 28] . Table 2 demonstrates the most recently reported microbial isolates from patients with bacteremic biliary tract infections [8, [25] [26] [27] 29] .
There is a lack of clinical trials examining the benefit of blood cultures in patients with acute biliary tract infections. On the other hand, there is an argument that every opportunity should be used to identify microorganisms and susceptibility testing in the era of antimicrobial resistance [45] .
Most of the bacteremic isolates reported ( Table 2 ) are organisms that do not form vegetations on normal cardiac valves or military abscesses [8] . Their intravascular presence does not lead to an extension of therapy or selection of multidrug regimens. We therefore recommend such cultures be taken only in high severity infections when such results might mandate changes in therapy [3, 4, 7] . Blood cultures are not routinely recommended for grade I community-acquired acute cholecystitis.
The SIS-NA/IDSA 2010 guidelines recommended against routine blood cultures for community-acquired intra-abdominal infections since the results do not change the management and outcomes [49] . This recommendation is carried forward in recent guidelines [43] . This is in part driven by a study of the clinical impact of blood cultures taken in the emergency department [51] . In this retrospective study, 1,062 blood cultures were obtained during the study period. Among them, 92 (9%) were positive. Of the positive blood cultures, 52 (5%) were true positive, and only 18 (1.6%) resulted in altered management.
Q2. What considerations should be taken when selecting antimicrobial agents for the treatment of acute cholangitis and cholecystitis?
When selecting antimicrobial agents, targeted organisms, pharmacokinetics and pharmacodynamics, local antibiogram, a history of antimicrobial usage, renal and hepatic function, and a history of allergies and other adverse events should be considered.
(Recommendation 1, level D). We suggest anaerobic therapy if a biliary-enteric anastomosis is present. (Recommendation 2, level C)
There are multiple factors to consider in selecting empiric antimicrobial agents. These include targeted organisms, local epidemiology and susceptibility data (antibiogram), alignment of in vitro activity (or spectrum) of the agents with these local data, characteristics of the agents such as pharmacokinetics and pharmacodynamics, and toxicities, renal and hepatic function, and any history of allergies and other adverse events with antimicrobial agents [13, 14, [17] [18] [19] [20] [21] [22] [23] [24] . A history of antimicrobial usage is important because recent (<6 months) antimicrobial therapy greatly increases the risk of resistance among isolated organisms.
Renal function should be estimated before dosing antimicrobial agents with the commonly used equation: Serum creatinine = (140-age) (optimum body weight (kg))/72 9 serum creatinine (mg/dl) [13, 14, 52] . Individual dosage adjustments for altered renal and hepatic function is available in several recent publications [53, 54] . Consultation with a clinical pharmacist is recommended if there are concerns.
Regarding the timing of therapy, therapy should be initiated as soon as the diagnosis of biliary infection is suspected. For patients in septic shock, antimicrobials should be administered within 1 h of recognition [7] . For other patients, as long as 6 h may be spent obtaining definitive diagnostic studies prior to beginning antimicrobial therapy. Antimicrobial therapy should definitely be started before any procedure, either percutaneous, endoscopic, or operative, is performed. In addition, anaerobic therapy is appropriate if a biliary-enteric anastomosis is present [49] .
Antimicrobial agents appropriate for use in the management of community-acquired acute cholangitis and cholecystitis Table 3 summarizes antimicrobial recommendations [1] . It should be kept in mind that in the treatment of cholangitis, source control (i.e. drainage) is an essential part of management. The indications and timing for drainage are provided in the severity and flowchart of the management sections regarding acute cholangitis [2] [3] [4] [5] [6] . There have been multiple reports on clinical isolates with multiple drug resistance from intra-abdominal infections worldwide, and biliary infections in particular [29, [31] [32] [33] [34] [35] [36] [37] 55] .
Recommendations for antimicrobial therapy are based primarily upon extrapolations of microbiologic efficacy and behavior of these agents against the more susceptible isolates treated in the cited clinical trials [56] [57] [58] [59] [60] [61] [62] [63] [64] [65] [66] . Some concerns about this approach to defining efficacy against resistant isolates has been raised [41] .
The use of severity of illness as a guide to antimicrobial agent selection has been questioned in the face of the increasing numbers of ESBL-producing E. coli and Klebsiella in the community. These organisms are not reliably susceptible to cephalosporins, penicillin derivatives, or fluoroquinolones. Previous guidelines have recommended that if more than 10-20% of community isolates of E. coli are so resistant, then empiric coverage should be provided for these organisms until susceptibility data demonstrates sensitivity to narrower spectrum agents [49] . Carbapenems, piperacillin/tazobactam, tigecycline, amikacin, and other newer agents such as ceftazidime/avibactum and ceftolozane/tazobactam may also be used to treat these isolates.
For grade III community-acquired acute cholangitis and cholecystitis, as initial therapy (empirical therapy), agents with anti-pseudomonal activities are recommended until causative organisms are identified. Pseudomonas aeruginosa is present in approximately 20% of previous series [24, 29] . However, recent large-scale data showed very few ranging from 1.1% to 3.1% among isolates from blood cultures and 2.5% to 3.6% from bile cultures obtained from patients with acute cholangitis, respectively [8] . P. aeruginosa is a known virulent pathogen and failure to empirically cover this organism in critically ill patients may result in excess mortality.
Enterococcus spp. is another important pathogen for consideration in patients with grade III communityacquired acute cholangitis and cholecystitis. Vancomycin is recommended to cover Enterococcus spp. for patients with grade III community-acquired acute cholangitis and/ or cholecystitis, until the results of cultures are available. Ampicillin can be used if isolated strains of Enterococcus spp. are susceptible to ampicillin. Ampicillin covers most of the strains of Enterococcus faecalis from communityacquired infections in general. For Enterococcus faecium, vancomycin is the drug of choice for empirical therapy. However, in many hospitals, vancomycin-resistant Enterococcus spp., both E. faecium and E. faecalis, have emerged as important causes of infection. Treatment for these organisms requires either linezolid or daptomycin. Surgeons and other physicians making treatment decisions for patients with healthcare-associated infections should be aware of the frequency of these isolates in their hospital and unit. Then regarding infrequently isolated anaerobes such as Bacteroides fragilis group, we suggest to cover these organisms empirically when a biliary-enteric anastomosis is present [49] .
For grade I and II community-acquired cholangitis and cholecystitis, Table 3 provides the agents appropriate for use. Clindamycin resistance among Bacteroides spp. is significant and the use of clindamycin is no longer recommended in other intra-abdominal infections [49] . Cefoxitin, cefmetazole, flomoxef, and cefoperazone/sulbactam are the agents in cephalosporins that have activities against Bacteroides spp. Cefoxitin is no longer recommended by the SIS-NA/IDSA 2010 guidelines due to high prevalence of resistance among Bacteroides spp. [49] . Local availability of agents as well as local susceptibility results are emphasized when choosing empirical therapy. Table 4 summarizes antimicrobial agents with high prevalence of resistance among Enterobacteriaceae [29, [31] [32] [33] [34] [35] [36] [37] . Ampicillin/sulbactam is one of the most frequently used agents for intra-abdominal infections. Nonetheless, the activity of ampicillin/sulbactam against E. coli, with or without ESBLs, has fallen to levels that prevent a recommendation for its use.
In the TG18, ampicillin/sulbactam is not recommended as empirical therapy if the local susceptibility is <80%. It is reasonable to use ampicillin/sulbactam as definitive therapy when the susceptibility of this agent is proven. Ampicillin/sulbactam may be used if susceptibility testing results are available.
Fluoroquinolone use is only recommended if the susceptibility of cultured isolates is known since antimicrobial resistance has been increasing significantly [29, [31] [32] [33] [34] [35] [36] [37] . This agent can also be used as an alternative agent for patients with b-lactam allergies.
Antimicrobial agents appropriate for use in the management of healthcare-associated acute cholangitis and cholecystitis
Since 2010, there have been very few clinical studies on antimicrobial therapy for patients with healthcare-associated acute cholangitis and cholecystitis.
There is no evidence to support any agent as optimal treatment of healthcare-associated acute cholangitis and cholecystitis. The principles of empirical therapy of healthcare-associated infections include using agents with antipseudomonal activity until definitive causative organisms are found.
The local prevalence of ESBL and/or carbapenemase producing Enterobacteriacea is critical information in selecting empirical agents. Optimal agents vary from institution to institution. Therefore, it is underscored that local susceptibility should be monitored strictly and periodically.
A multi-disciplinary approach would be beneficial to provide and discuss appropriate antimicrobial agents in the institution, region, and country. Table 3 provides empirical agents (presumptive therapy) for healthcare-associated acute cholangitis and cholecystitis. Vancomycin is recommended when patients are colonized with resistant Gram-positive bacteria such as methicillinresistant Staphylococcus aureus and/or Enterococcus spp. or these multidrug-resistant Gram-positives are of concern. Staphylococcus aureus is not a common isolate for acute biliary infections as Enterococcus spp. In recent study, Staphylococcus aureus was isolated less than 1% both from blood and bile for patients with acute cholangitis [8] .
Vancomycin resistant Enterococcus (VRE) should be covered empirically with linezolid or daptomycin if this organism is known to be colonizing the patient, if previous treatment included vancomycin, and/or if the organism is common in the community.
Isolation of Bacteroides fragilis group was 1.1% from blood cultures, and 1.6% from bile cultures among patients with acute cholangitis [8] . For empirical therapy for anaerobes such as the Bacteroides fragilis group, we suggest to cover these organisms empirically in the presence of a biliary-enteric anastomosis [49] .
Is it necessary for agents used in acute biliary infections to be concentrated in bile?
Historically, biliary penetration of agents has been considered in the selection of antimicrobial agents. However, there is considerable laboratory and clinical evidence that as obstruction occurs, secretion of antimicrobial agents into bile stops [10] . Recent international guidelines for acute calculous cholecystitis summarized the bile to serum concentration ratio and recommend to select agents with good infected sites penetration [50] . Well-designed randomized clinical trials comparing agents with or without good biliary penetration are needed to determine the clinical relevance and significance of biliary penetration in treating acute biliary infections.
How should highly resistant causative organisms be managed in treating acute cholangitis and cholecystitis?
Extended-spectrum beta-lactamases-producing E. coli is highly susceptible to carbapenems and to tigecycline. In multiple areas of the world, highly resistant Klebsiella spp. and E. coli with carbapenemases are seen [41, [67] [68] [69] . The widely accepted rule for empirical therapy is that resistant organisms occurring in more than 10-20% of patients should be treated. Colistin is the salvage agent for the above multidrug-resistant Gram-negative bacilli epidemic strains [55, 69] . This agent is toxic, dosing is uncertain, and its use should involve consultation with infectious disease specialists [55] . Newer agents such as ceftazidime/avibactam and ceftolozane/tazobactam has limited evidence for use among patients with acute cholangitis and cholecystitis.
In TG18, endorsed from TG13 [1] , carbapenems, piperacillin/tazobactam, and ceftazidime or cefepime, each combined with metronidazole have been recommended when the prevalence of resistant Pseudomonas aeruginosa, ESBL-producing Enterobacteriaceae, Acinetobacter or other multidrug-resistant Gram-negative bacilli is less than 20% [49] . For ESBL-producing Enterobacteriaceae, carbapenems, piperacillin/tazobactam, and aminoglycosides are recommended. For Pseudomonas aeruginosa, if the prevalence of resistance to ceftazidime is more than 20%, carbapenems, piperacillin/tazobactam, and aminoglycosides are empirically recommended until culture and susceptibility testing results are available.
Q3. What is the optimal duration and route of antimicrobial therapy for patients with acute cholangitis?
Once the source of infection is controlled, antimicrobial therapy for patients with acute cholangitis is recommended for the duration of 4 to 7 days. (Recommendation 1, level C) Literature was searched using PubMed and Cochrane Library using the key words of (acute cholangitis* OR acute biliary tract infections*) AND (antimicrobial therapy* OR antibiotics*) AND duration of therapy.* MeSH was also used for each word. There was a total of 151 articles from PubMed, 16 from Cochrane Controlled Clinical Trials (CCT), and one from Cochrane Clinical Database of Systematic Reviews (CDSR). Among them, selection criteria were either randomized studies or observational studies. The articles that met the selection criteria were screened initially by title, then if it was difficult to judge, the abstract was also reviewed. As a result, there were four relevant articles found.
Uno et al. [70] compared retrospectively the outcomes among patients with bacteremic acute cholangitis due to Gram-negative bacilli who received antimicrobial therapy over either 14 or 10 days. There were no differences between the two groups in 30-day mortality and recurrence rate within 3 months. There were statistically significant differences in the lengths of stay (17.5 days vs. 14 days, P < 0.01). van Lent et al. [71] reported that in their single institution, there were no differences in the recurrence rate for acute cholangitis between the patients who received less than 3-day therapy versus more than 5-day therapy once the source of infection was controlled among patients with acute cholangitis. Kogure et al. [72] conducted a prospective observational study to investigate how long antimicrobial therapy should be administered for patients with acute cholangitis after successful biliary drainage. In this study, 18 patients were analyzed for recurrent cholangitis within 3 days after discontinuing antimicrobial therapy. There were no recurrences noted. Park et al. [73] conducted a randomized study to compare the recurrence rate and 30-day mortality among patients with bacteremic cholangitis due to ciprofloxacin-susceptible Enterobacteriacae who underwent successful biliary drainage and received either conventional intravenous therapy or 6-day intravenous antimicrobial therapy followed by oral therapy. In this study, there were no differences between the two groups in the recurrence of cholangitis and 30-day mortality. In the TG18, the duration of therapy for patients with acute cholangitis is for 4 to 7 days once the source of infection is controlled by integrating the above studies and expert opinion (Table 5 ). When bacteremia with Gram-positive bacteria such as Enterococcus spp. and Streptococcus spp. is present, it is prudent to offer antimicrobial therapy for 2 weeks since these organisms are well-known to cause infective endocarditis. The incidence of endocarditis among patients with acute cholangitis has been reported 17 (0.3%) out of 6,147 patients with acute cholangitis [8] .
In Literature was searched using PubMed and Cochrane Library using the key words of (acute cholecystitis* OR acute biliary tract infections*) AND (antimicrobial therapy* OR antibiotics*) AND duration of therapy.* MeSH was also used for each word.
There was a total of 51 articles from PubMed, 21 from CCT, and one from CDSR. Among them, selection criteria were either randomized studies or observational studies. The articles that met the selection criteria were screened initially by title, then if it was difficult to judge, the abstract was also reviewed. As a result, there were four relevant articles found: three randomized controlled trials (RCTs) [74] [75] [76] and one observational study [77] .
TG13 [1] and SIS-IDSA 2010 [49] recommended postoperative antimicrobial therapy for different durations, ranging from 24 h to 7 days depending on the severity of cholecystitis given the lack of high-quality evidence. Recently, two RCTs assessing the non-inferiority of no postoperative antimicrobial therapy with postoperative antimicrobial therapy for patients with mild or moderate acute cholecystitis who underwent early cholecystectomy were conducted [74, 75] . Although non-inferiority was not proven in either RCT, there was no clinically significant difference. The results of the two RCTs were integrated and the risk difference for postoperative infection was 0.01 (95% CI À0.04-0.06) (Fig. 1) . Considering the disadvantages of extended antimicrobial therapy, including increased medical costs, prolonged hospital stay, and increased bacterial resistance, the antimicrobial therapy should be limited to before and at the time of surgery for Grade I and II acute cholecystitis. Some patients would need extended postoperative antibiotics depending on their condition.
For Grade III acute cholecystitis, there are scarce data available. Hence, we suggest the expert opinion of continuing antimicrobial therapy for 4-7 days after the source of infection is controlled (Table 5 ). When bacteremia with Gram-positive bacteria is present, administering antimicrobial therapy for 2 weeks is prudent and recommended to decrease the risk of infective endocarditis.
In the consensus meeting, there was a statement by the member that there were no sufficient data to support this duration of therapy for patients with Grade III acute cholecystitis, and that it would be difficult to recommend this. Fig. 1 This meta-analysis was performed by integrating two randomized studies, references [74] and [75] (Antimicrobial therapy for special conditions) In patients with pericholecystic abscesses or perforation of the gallbladder, treatment with an antimicrobial regimen as listed in Table 3 is recommended. Therapy should be continued until the patient is afebrile, with a normalized white count, and without abdominal findings. (Recommendation  1, level D) In most cases, cholecystectomy removes the infection, and little if any infected tissue remains. Under these circumstances, there is no benefit to antimicrobial therapy extending beyond 24 h [74, 75] .
Randomized clinical trials for antimicrobial therapy of acute cholecystitis are limited [60, [62] [63] [64] [65] . In these randomized studies, comparisons were made such as ampicillin plus tobramycin versus piperacillin or cefoperazone, pefloxacin versus ampicillin and gentamicin, cefepime versus mezlocillin plus gentamicin [14, 60, 63, 65] . There were no significant differences between the agents compared. In the TG18, the agents considered as appropriate therapy, and listed in Table 3 , have all been used in RCTs of intra-abdominal infections. These studies included patients with pathologically advanced cholecystitis (abscess or perforation). Table 3 is provided for both communityacquired and healthcare-associated acute cholecystitis.
Antimicrobial therapy after susceptibility testing results are available
Once susceptibility testing results of causative microorganisms are available, specific therapy (or definitive therapy) should be offered. This process is called de-escalation [7] . Agents in Table 4 can be used safely once the susceptibility is proven.
Conversion to oral antimicrobial agents
Patients with acute cholangitis and cholecystitis who can tolerate oral feeding may be treated with oral therapy [78] . Depending on the susceptibility patterns of the organisms identified, oral antimicrobial agents such as fluoroquinolones (ciprofloxacin, levofloxacin, or moxifloxacin), amoxicillin/clavulanic acid, or cephalosporins may also be used. Table 6 lists commonly used oral antimicrobial agents with good bioavailabilities.
Use of antibiotic irrigation
There has been continuing interest in irrigation of surgical fields with antimicrobial agents, and the subject has recently been reviewed [79] . The authors concluded that topical antimicrobial agents are clearly effective in reducing wound infections and may be as effective as the use of systemic antimicrobial agents. The combined use of systemic and topical antimicrobial agents may have additive effects, but this is lessened if the same agent is used for both topical and systemic administration.
Conclusions
In TG18, antimicrobial agents appropriate for use as empirical therapy for community-acquired and healthcareassociated infections are provided. Globally increasing and spreading antimicrobial resistance, antimicrobial stewardship should be underscored and implemented for prudent antimicrobial usage in each institution. Local, national, and international continuous monitoring of antibiogram would provide safe and appropriate therapy for patients with acute cholangitis and cholecystitis in a timely fashion. More definitive studies to indicate the appropriate duration of antimicrobial therapy for patients with bacteremic cholangitis and cholecystitis are warranted. 
